Compare Payoneer Global Inc (PAYO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs TransMedics Group Inc — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Payoneer Global Inc and TransMedics Group Inc are close in size by market cap, and Payoneer Global Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and TransMedics Group Inc for 24 Days on average.
| PAYO | TMDX | |
|---|---|---|
Market Cap | $2.43B | $2.74B |
Volume | 1,342,701 | 949,331 |
Sector | Technology | Health |
52-Week High | $7.18 | $150.42 |
52-Week Low | $4.27 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | $2.17B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, down 0.28% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but maintains strong revenue growth and a 78% gross margin. Recent news highlights the renewal of its partnership with Etsy through 2029 and ongoing acquisition discussions with Nuvei.
The stock presents a mixed outlook: analyst consensus is 60% buy with no sell ratings, but elevated P/E of 51.18 and recent earnings misses pose valuation and execution risks. The pending acquisition adds uncertainty, while expansion into India offers growth potential. Investors should weigh strong fundamentals against high expectations and integration challenges.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
